Etheros Pharmaceuticals develops small‑molecule enzyme mimetics that replicate the activity of superoxide dismutase and catalase to protect neural tissue from oxidative and inflammatory damage. Their lead compound has shown neuroprotection in multiple double‑blind, placebo‑controlled animal studies and extends median lifespan of wild‑type mice by about 15% when administered from middle age.
Funding
Funding not disclosed
Founders
Product
Problem
Neural tissue is highly vulnerable to oxidative and inflammatory damage, yet existing treatments for neurodegeneration and age‑related decline provide limited protection against these mechanisms.
Solution
Etheros creates small‑molecule mimetics of the endogenous enzymes superoxide dismutase and catalase to neutralize reactive oxygen species and reduce inflammation in the brain. The lead compound demonstrates neuroprotective activity across multiple double‑blind, placebo‑controlled animal models and prolongs median lifespan in wild‑type mice by approximately 15% when treatment starts at middle age. By delivering enzyme‑like activity in a drug‑like format, the platform aims to provide a disease‑modifying therapy for neurodegenerative disorders and a potential health‑span extension agent.
Target Audience
Primary customers are pharmaceutical developers and biotech companies focused on treatments for neurodegenerative diseases and longevity research, as well as academic and clinical research groups evaluating disease‑modifying interventions.
Features
- Small‑molecule design that reproduces the catalytic functions of superoxide dismutase and catalase
- Demonstrated neuroprotection in diverse double‑blind, placebo‑controlled animal studies
- Extends median lifespan in wild‑type mice by ~15% when administered from mid‑life
- Oral or systemic administration potential with favorable pharmacokinetics for central nervous system exposure
- Scalable chemical synthesis enabling consistent manufacturing and low immunogenic risk